Mixed Phenotype Acute Leukemia: Disease Characteristics Research Report

Scope. This synthesis prioritizes WHO/ICC-era sources and 2023–2024 primary studies. Evidence labels distinguish human cohorts, expert reviews, experimental models, and trial records. DOI links are supplied because the retrieved records did not consistently expose PMIDs; PMIDs are therefore not invented. The data are aggregated disease-level evidence, not individual EHR data.

Executive summary

Mixed phenotype acute leukemia (MPAL) is a rare, aggressive acute leukemia of ambiguous lineage in which the leukemic blasts meet lineage-defining criteria for more than one hematopoietic lineage. B/myeloid MPAL is most common, followed by T/myeloid MPAL. WHO-HAEM5 and the 2022 International Consensus Classification (ICC) combine immunophenotype with genetics and recognize genetically defined groups involving BCR::ABL1, KMT2A, ZNF384, and BCL11B. Current evidence generally favors an ALL-type induction regimen, addition of a tyrosine-kinase inhibitor (TKI) for BCR::ABL1-positive disease, close measurable residual disease (MRD) monitoring, and risk-adapted allogeneic hematopoietic stem-cell transplantation (HSCT), especially in adults. Pediatric patients who clear MRD early can frequently obtain durable remission with ALL therapy without routine HSCT. Recent single-cell studies identify marked inter- and intrapatient heterogeneity but a shared primitive/stem-like state that may explain lineage plasticity, relapse, and lineage switching. (sherban2025acuteleukemiaof pages 12-16, sherban2025acuteleukemiaof pages 20-24, sherban2025acuteleukemiaof pages 1-6, mumme2023singlecellrnasequencing pages 1-2, peretz2024multiomicsinglecell pages 1-2)

Table: Concise knowledge-base summary table for mixed phenotype acute leukemia covering classification, epidemiology, molecular features, diagnostics, treatment, prognosis, and recent translational developments. It highlights key numbers and cites the available evidence contexts and trial identifiers for rapid downstream curation.

1. Disease information

Definition and classification

MPAL belongs to the category acute leukemia of ambiguous lineage (ALAL). Unlike acute undifferentiated leukemia, MPAL has convincing evidence of commitment to at least two lineages. Disease may be:

• Biphenotypic: one blast population co-expresses lineage-defining markers.
• Bilineal/trilineal: two or more immunophenotypically discrete blast populations together constitute the acute leukemia; bilineal disease may have inferior outcomes.
• Phenotypic groups: B/myeloid (approximately 67%), T/myeloid, rare B/T, B/T/myeloid, or T/megakaryoblastic disease. (sherban2025acuteleukemiaof pages 6-9, sherban2025acuteleukemiaof pages 1-6)

WHO/ICC exclude cases whose mixed immunophenotype occurs in an otherwise defining AML entity, including AML with t(8;21)/RUNX1::RUNX1T1, inv(16)/CBFB::MYH11, or t(15;17)/PML::RARA. Therapy-related or secondary AML with aberrant lymphoid markers must likewise be separated from genuine MPAL. (sherban2025acuteleukemiaof pages 6-9, weinberg2024howtothink pages 5-6)

Identifiers and synonyms

• MONDO: MONDO:0020743.
• Parent concept: acute leukemia of ambiguous lineage, MONDO:0019460.
• Synonyms: mixed-phenotype acute leukemia, mixed phenotype acute leukaemia, MPAL, biphenotypic acute leukemia, bilineal acute leukemia, mixed-lineage acute leukemia. “Biphenotypic leukemia” is historical and should not be treated as exactly synonymous in modern classification.
• MeSH/OMIM/Orphanet: no reliably verified MPAL-specific identifiers were exposed by the retrieved primary records. MPAL is a somatic cancer category rather than a classic single-gene Mendelian OMIM disorder.
• ICD: ICD-10-CM lacks a robust phenotype-specific MPAL code and cases are commonly mapped under acute leukemia/acute leukemia of ambiguous cell type according to local coding rules; ICD-11 classification should be verified against the deploying jurisdiction’s current release.

Open Targets independently maps MPAL to MONDO:0020743 and identifies clinically relevant lineage targets CD19 and the CD3 complex; this is target-association evidence, not proof that these genes cause MPAL. (OpenTargets Search: mixed phenotype acute leukemia)

2. Etiology, risk, and protective factors

MPAL is predominantly a sporadic clonal somatic malignancy. Its proximate causes are acquired driver rearrangements/mutations and epigenetic dysregulation in a hematopoietic stem or early progenitor cell capable of multilineage differentiation. There is no single necessary causal gene.

• Genetic drivers: BCR::ABL1, KMT2A rearrangements, ZNF384 fusions, and BCL11B activation are the best-established recurrent lesions. Cooperating alterations affect RUNX1, WT1, ETV6, CEBPA, FLT3/JAK–STAT, RAS, IKZF1, and PAX5, among others. (sherban2025acuteleukemiaof pages 9-12, weinberg2024howtothink pages 5-6)
• Age: KMT2A-rearranged disease is enriched in infants/children; BCR::ABL1-positive B/myeloid MPAL is enriched in older patients. ZNF384-rearranged disease is particularly prominent in pediatric B/myeloid MPAL. (sherban2025acuteleukemiaof pages 9-12)
• Secondary disease: prior myelodysplasia, cytotoxic therapy, or an AML-type mutation pattern should raise concern for secondary AML with mixed phenotype rather than de novo MPAL. In one comparison, secondary AML with mixed phenotype had median overall survival of 10.3 months versus 42.8 months for MPAL and responded very differently to ALL induction. (sherban2025acuteleukemiaof pages 6-9)

No MPAL-specific, reproducible associations with smoking, alcohol, diet, infection, occupation, pollution, or a defined gene–environment interaction were identified. General leukemia risks such as ionizing radiation and prior cytotoxic therapy should not be automatically annotated as MPAL-specific causes. No validated genetic or environmental protective factors are known. These are evidence gaps, not demonstrations that such effects cannot exist.

3. Phenotypes

MPAL has an acute, severe, progressive presentation at any age. Clinical manifestations largely result from marrow replacement and tissue infiltration rather than from the mixed immunophenotype itself.

A 94-patient pediatric cohort was 89% B/myeloid, 94% MPO-positive, and 90% CD19-positive; 70% had presenting leukocytes below 50,000/µL and 68% were CNS1. These figures describe one US cohort rather than universal frequencies. (oberley2020significanceofminimal pages 2-3)

Quality of life. MPAL-specific EQ-5D, SF-36, PROMIS, or utility studies were not identified. Expected impacts include hospitalization, infection isolation, transfusion dependence, treatment toxicity, impaired schooling/work, fertility concerns, and psychological burden, but these should be labeled extrapolations from acute leukemia care rather than MPAL-specific measured effects.

4. Genetic and molecular information

Recurrent somatic lesions

• BCR::ABL1: approximately 15–20%, usually B/myeloid and enriched with increasing age. It encodes a constitutively active ABL tyrosine kinase and is therapeutically actionable with a TKI. (sherban2025acuteleukemiaof pages 9-12)
• KMT2A rearrangement: approximately 10%; enriched in infants and younger children, usually B/myeloid, and associated with especially poor prognosis. (sherban2025acuteleukemiaof pages 12-16, sherban2025acuteleukemiaof pages 9-12)
• ZNF384 rearrangement: reported in up to 50% of pediatric B/myeloid MPAL but uncommon in adult MPAL. Fusion partners include EP300, CREBBP, TCF3, and others. (sherban2025acuteleukemiaof pages 9-12)
• BCL11B activation/rearrangement: about 10–15% of MPAL overall and up to one-third of T/myeloid MPAL; it links T/myeloid MPAL biologically to early T-cell precursor ALL. (sherban2025acuteleukemiaof pages 9-12, weinberg2024howtothink pages 5-6)
• Other alterations: T/myeloid disease has relatively high mutation burden involving WT1, ETV6, RUNX1, CEBPA, FLT3 and JAK–STAT signaling; B/myeloid disease more often has IKZF1, PAX5, and RAS-pathway lesions. Complex karyotype is adverse. (sherban2025acuteleukemiaof pages 9-12)

These are somatic structural variants or somatic sequence variants in the leukemia clone. Population allele frequencies in gnomAD are therefore generally not meaningful for the defining fusions. Patient-specific germline testing is appropriate when age, personal/family history, or the variant allele pattern suggests an inherited leukemia-predisposition syndrome; MPAL itself does not have a defined Mendelian inheritance pattern.

Epigenetics and functional consequence

Adult integrative profiling separated MPAL into AML-like and ALL-like DNA-methylation groups; lineage-matched therapy produced complete response in 72% versus 22% with molecularly mismatched treatment, supporting a biological rather than merely descriptive role for epigenetic lineage state. Genetically similar blast compartments can display different phenotypes, indicating that epigenetic regulation contributes substantially to lineage ambiguity. (sherban2025acuteleukemiaof pages 12-16, sherban2025acuteleukemiaof pages 9-12)

In ZNF384-rearranged experimental systems, fusion proteins occupy enhancer/intragenic regions, increase H3 lysine acetylation, deregulate stem-cell transcription factors, skew HSPCs toward myeloid differentiation, and promote self-renewal. The study’s abstract states that the fusions “promote hematopoietic expansion, myeloid lineage skewing, and self-renewal.” NRAS^G12D or another cooperating proliferative lesion was required for fully penetrant leukemia in mouse HSPCs, whereas human HSPCs developed B/myeloid leukemia. (dickerson2022znf384fusiononcoproteins pages 15-15)

5. Environmental and infectious information

There is no established MPAL-specific infectious agent, toxin, dietary exposure, exercise pattern, alcohol association, or smoking association. MPAL is not contagious. Prior chemotherapy/radiotherapy may precede secondary myeloid disease with mixed marker expression, but rigorous distinction from de novo MPAL is essential. No validated MPAL-specific chemopreventive or lifestyle intervention exists.

6. Mechanism and pathophysiology

Causal chain

1. Upstream initiation: an acquired rearrangement or mutation occurs in a multipotent HSPC or early progenitor.
2. Lineage-program disruption: fusion oncoproteins or transcription-factor dysregulation alter enhancer use, chromatin state, and lineage-specifying transcription.
3. Cooperating proliferation/survival signaling: RAS, FLT3, JAK–STAT, ABL1, or related lesions increase survival and expansion.
4. Stemness and plasticity: the clone retains multilineage differentiation potential, generating biphenotypic or bilineal blast compartments.
5. Marrow/tissue expansion: blasts suppress normal erythropoiesis, granulopoiesis, and megakaryopoiesis, producing anemia, infection, bleeding, and tissue infiltration.
6. Treatment selection: lineage-targeted therapy can select phenotypically distinct subclones or promote lineage switch; persistent stem-like/MRD compartments seed relapse. (sherban2025acuteleukemiaof pages 9-12, mumme2023singlecellrnasequencing pages 1-2, peretz2024multiomicsinglecell pages 1-2, dickerson2022znf384fusiononcoproteins pages 15-15)

Molecular profiling and advanced technologies

The 2023 pediatric scRNA-seq study analyzed >40,000 cells from nine marrow samples. B/myeloid and T/myeloid MPAL had distinct signatures; both overexpressed MAP2K2 and CD81, while HBEGF marked B/myeloid and PTEN marked T/myeloid disease. T/myeloid MPAL overlapped strongly with early T-cell precursor ALL, and relapsed samples showed IL-16-pathway upregulation. The abstract concludes that the subtypes have “distinct scRNAseq profiles from each other, AML, and ALL.” (mumme2023singlecellrnasequencing pages 1-2)

A September 2024 adult multiomic study profiled 14 newly diagnosed patients and found that genotype or transcriptome did not reliably predict immunophenotype. A shared primitive transcriptional state correlated with differentiation potential and poorer survival; its 95-gene MPAL95 score predicted survival in an independent bulk-RNA cohort. The authors’ central conclusion was that MPAL blasts express a “shared stem cell-like transcriptional profile indicative of high differentiation potential.” (peretz2024multiomicsinglecell pages 1-2)

Suggested annotations include GO:0030097 hemopoiesis, GO:0045165 cell fate commitment, GO:0008283 cell population proliferation, GO:0007049 cell cycle, GO:0043066 negative regulation of apoptotic process, GO:0045595 regulation of cell differentiation, GO:0006355 regulation of transcription, and GO:0040029 regulation of gene expression, epigenetic. Relevant cell types include hematopoietic stem cell, hematopoietic multipotent progenitor, lymphoid progenitor, myeloid progenitor, B-lineage lymphoblast, T-lineage lymphoblast, and myeloblast; exact CL identifiers should be ontology-release validated before production ingestion.

7. Anatomical structures affected

• Primary: bone marrow (UBERON:0002371), peripheral blood, and hematopoietic/lymphoid system.
• Secondary: spleen (UBERON:0002106), liver (UBERON:0002107), lymph nodes (UBERON:0000029), CNS, skin, and other extramedullary sites.
• Cellular: leukemic HSPC/progenitor and its phenotypically diverse blast descendants.
• Subcellular: nucleus and chromatin for transcription-factor fusions; cytoplasm/membrane for lineage markers; cytoplasmic and nuclear tyrosine-kinase signaling for BCR::ABL1.
• Lateralization: not applicable.

Non-leukemic pediatric MPAL/lymphoma can occur in lymph node, skin, or other extranodal sites. In one prospective series, 11 such cases were found among 146 lymphoblastic lymphomas; all entered complete remission on a lymphoblastic lymphoma protocol. (martin‐guerrero2019non‐leukemicpediatricmixed pages 1-4, martin‐guerrero2019non‐leukemicpediatricmixed pages 16-17)

8. Temporal development

Onset is acute, developing over days to weeks clinically, although somatic evolution precedes symptoms. It occurs from infancy through old age. Untreated disease is rapidly progressive and not self-limited. Clinical phases are diagnosis, induction, remission/MRD assessment, consolidation/maintenance, and either durable remission or relapse/refractory disease; conventional solid-tumor AJCC staging is not applicable.

The key intervention window is induction and early MRD clearance. In children, end-of-induction MRD positivity was strongly associated with inferior 5-year EFS (HR 6.00) and OS (HR 9.57). Relapse can preserve phenotype, become more homogeneous, or undergo lineage switch. (oberley2020significanceofminimal pages 1-2)

9. Inheritance, epidemiology, and population

ALAL/MPAL represents approximately 2–3% of acute leukemias; a recent review cited a SEER incidence of approximately 0.35 per million person-years. Broader publications have reported 1–5%, reflecting changes in diagnostic criteria and referral populations. (orgel2020mixed‐phenotypeacuteleukemia pages 1-2, sherban2025acuteleukemiaof pages 1-6)

A nine-case pediatric single-cell cohort had mean age 13.4 years and was 78% male, whereas the larger 94-patient US cohort was 66% male and 55% Hispanic. These observations do not establish a biological ethnic predisposition and may reflect ascertainment and center demographics. (mumme2023singlecellrnasequencing pages 4-5, oberley2020significanceofminimal pages 2-3)

There is no standard autosomal-dominant, autosomal-recessive, X-linked, mitochondrial, founder, carrier-frequency, anticipation, or germline-mosaicism model for MPAL. Penetrance and carrier frequency are therefore not applicable at the disease level. Germline predisposition should be recorded separately when demonstrated.

10. Diagnostics

Recommended workflow

1. CBC, differential, peripheral smear, coagulation and tumor-lysis chemistry.
2. Bone-marrow aspirate/core biopsy for morphology and blast burden.
3. Multiparameter flow cytometry with intensity compared with normal counterparts and assessment for one versus multiple blast populations.
4. Karyotype and FISH, including BCR::ABL1 and KMT2A; add probes guided by phenotype.
5. Broad DNA NGS plus RNA fusion sequencing, because cryptic ZNF384/BCL11B and kinase fusions may be missed by karyotype or limited panels.
6. HLA typing and baseline organ assessment if HSCT is plausible.
7. MRD assay design at diagnosis, preserving all abnormal compartments and considering fusion-specific PCR/NGS where validated.

Lineage-defining criteria

• Myeloid: myeloperoxidase (MPO), or monocytic differentiation supported by at least two markers such as CD11c, CD14, CD64, lysozyme, or nonspecific esterase.
• T lineage: strong surface or cytoplasmic CD3; recent guidance uses intensity greater than 50% of mature T-cell levels.
• B lineage: strong CD19 plus appropriate additional B markers; recent guidance compares intensity with normal B-cell progenitors.
• Acute disease generally requires an aggregate ≥20% blasts, while genetically defined entities and classification-specific exceptions require careful WHO/ICC application. (sherban2025acuteleukemiaof pages 6-9, sherban2025acuteleukemiaof pages 1-6)

Differential diagnosis

Exclude AML with defining recurrent genetics, B-ALL or T-ALL with aberrant myeloid antigen expression, early T-cell precursor ALL, AML with minimal differentiation, acute megakaryoblastic leukemia, secondary/therapy-related AML, blast-phase CML, myeloid/lymphoid neoplasms with eosinophilia and kinase rearrangement, and acute undifferentiated leukemia. Merely expressing CD13, CD33, CD7, or another cross-lineage antigen is insufficient for MPAL.

No population, newborn, prenatal, carrier, or asymptomatic screening is recommended. WES/WGS may help unresolved cases but does not replace flow cytometry and RNA fusion detection. Mitochondrial or repeat-expansion testing is not relevant.

11. Outcome and prognosis

In a centrally reviewed Children’s Oncology Group cohort, 5-year EFS was 72%±8% and OS 77%±7%. Children treated with ALL chemotherapy alone without HSCT had 5-year EFS 75%±13% and OS 84%±11%, although selection bias limits causal interpretation. (orgel2020mixed‐phenotypeacuteleukemia pages 1-2)

In an adult transplant registry of 519 MPAL patients, 3-year relapse was 31.4%, non-relapse mortality 22.1%, leukemia-free survival 46.5%, and OS 56.3%. Another adult series reported 5-year OS of 54% after transplantation; MRD-negative patients had 75.8% versus 45.2% survival. (sherban2025acuteleukemiaof pages 20-24)

Adverse factors include older age, complex karyotype, KMT2A rearrangement, secondary AML-type biology, induction failure, and persistent MRD. BCR::ABL1-positive prognosis has improved substantially with TKI therapy; one synthesis reported median OS 53.6 months and 5-year OS 49%. (sherban2025acuteleukemiaof pages 12-16, sherban2025acuteleukemiaof pages 9-12)

Major complications include bacterial/fungal infection, hemorrhage, tumor lysis, leukostasis, organ toxicity, infertility, graft-versus-host disease, relapse, and lineage switch. MPAL-specific long-term disability and quality-of-life statistics remain sparse.

12. Treatment

Current strategy

1. ALL-type induction is generally preferred over AML or hybrid induction. A synthesis found superior complete remission and OS with ALL therapy; pediatric 5-year EFS was reported as 80%±4% with ALL-type versus 36%±7.2% with AML-type therapy. Hyper-CVAD produced CR/CRi in 84% in an adult series. (sherban2025acuteleukemiaof pages 12-16)
2. BCR::ABL1-positive MPAL: add an ABL TKI (e.g., imatinib, dasatinib, ponatinib selected by patient and mutation context) promptly.
3. MRD-adapt therapy: repeat flow and/or molecular MRD after induction and consolidation. Pediatric end-of-induction MRD negativity below 0.01% occurred in 70% and strongly predicted favorable outcome. (oberley2020significanceofminimal pages 1-2)
4. HSCT: not routinely necessary for every pediatric patient who clears MRD; consider in adults, persistent MRD, induction failure, adverse genetics, or relapse. Conditioning choice and comorbidity must be individualized. (sherban2025acuteleukemiaof pages 20-24)
5. Relapse/targeted therapy: CD19-positive disease may receive blinatumomab; CD19/CD22-targeted antibodies or CAR-T approaches are biologically plausible but can select lineage-negative or switched clones. Venetoclax-based therapy is investigational. ZNF384-rearranged preclinical models suggest FLT3 inhibition. (dickerson2022znf384fusiononcoproteins pages 15-15, NCT07222579 chunk 3)

Suggested NCIT concepts include acute lymphoblastic leukemia chemotherapy regimen, hyper-CVAD regimen, tyrosine kinase inhibitor therapy, blinatumomab, chimeric antigen receptor T-cell therapy, allogeneic hematopoietic stem-cell transplantation, measurable residual disease assessment, venetoclax, azacitidine, and supportive transfusion therapy; exact NCIT codes should be release validated.

Current trials and real-world implementation

• NCT05327894 (Interfant-21): recruiting phase 3 protocol for infants with KMT2A-rearranged ALL or MPAL; target enrollment 160. Open Targets links this trial to CD19/CD3-relevant MPAL biology. (OpenTargets Search: mixed phenotype acute leukemia)
• NCT04872478: recruiting phase 1 MRX-2843 study in adolescent/adult relapsed or refractory AML, ALL, or MPAL; target enrollment 50.
• NCT07222579: recruiting subcutaneous blinatumomab study for adult CD19-positive MPAL, including chemotherapy-ineligible, MRD-positive, and relapsed/refractory cohorts. (NCT07222579 chunk 3)
• NCT07517510: phase 2 HVA—homoharringtonine, venetoclax, and azacitidine—for newly diagnosed adult MPAL; planned n=40, with 2026 start. (NCT07517510 chunk 1)
• NCT07573670: phase 2 BCL-2 inhibitor plus azacitidine for newly diagnosed BCR::ABL1-negative MPAL; planned n=52. (NCT07573670 chunk 2)
• NCT02135874: completed phase 2 hybrid clofarabine/idarubicin/cytarabine/vincristine/dexamethasone study, illustrating prior attempts to cover both myeloid and lymphoid biology. (NCT02135874 chunk 2)

These trials are investigational and do not establish efficacy. Supportive care follows acute leukemia standards: tumor-lysis prophylaxis, antimicrobial prophylaxis, irradiated/leukoreduced blood products, fertility preservation, nutrition, psychosocial care, and rehabilitation after deconditioning.

13. Prevention

No MPAL-specific primary prevention, vaccine, screening program, prophylactic medication, or validated behavioral intervention exists. Sensible measures include minimizing unnecessary ionizing radiation and carcinogenic exposure and following survivors of prior cytotoxic therapy according to established oncology guidance, but there is no evidence that these measures specifically prevent MPAL.

Secondary prevention is limited to prompt evaluation of unexplained cytopenias, leukocytosis, bruising, infection, or constitutional symptoms; routine screening of asymptomatic people is not justified by the very low incidence. Tertiary prevention includes infection and tumor-lysis prophylaxis, MRD-guided relapse prevention, vaccination planning after chemotherapy/HSCT, and survivorship surveillance. Genetic counseling is indicated only where a separate germline predisposition is suspected or demonstrated.

14. Other species and natural disease

No well-defined, naturally occurring veterinary disease that is taxonomically equivalent to human WHO/ICC MPAL was identified. Dogs, cats, and other animals can develop leukemias with ambiguous immunophenotypes, but diagnostic comparability and recurrent molecular drivers are insufficient to annotate these as the same disease. MPAL is not infectious or zoonotic, and cross-species transmission is not applicable.

15. Model organisms and experimental systems

The strongest disease models are molecularly engineered systems rather than spontaneous animal disease:

• EP300::Znf384 knock-in mouse and virally transduced mouse HSPCs: reproduce progenitor expansion, myeloid skewing, and self-renewal; a cooperating NRAS^G12D lesion was required for fully penetrant leukemia. Limitation: engineered genotype and murine hematopoiesis do not reproduce all human MPAL heterogeneity. (dickerson2022znf384fusiononcoproteins pages 15-15)
• Human CD34+ HSPCs expressing ZNF384 fusion: generate B/myeloid leukemia and more directly model human lineage ambiguity. (dickerson2022znf384fusiononcoproteins pages 15-15)
• Patient-derived xenografts: preserve aspects of human clone biology and support drug testing. A ZNF384-rearranged xenograft showed marked in-vivo response to the FLT3 inhibitor gilteritinib. Limitation: immunodeficient recipients cannot model an intact immune microenvironment. (dickerson2022znf384fusiononcoproteins pages 15-15)
• Primary single-cell datasets: pediatric scRNA-seq and adult DNA/RNA/protein multiomics resolve intratumoral states but are observational and based on nine and 14 patients, respectively. (mumme2023singlecellrnasequencing pages 1-2, peretz2024multiomicsinglecell pages 1-2)

Relevant species are Homo sapiens (NCBI Taxon 9606) and Mus musculus (NCBI Taxon 10090). Useful resources include MGI/IMSR for engineered mice, Cellosaurus for cell models, and GEO/SRA for transcriptomic datasets.

Evidence limitations and expert interpretation

The central uncertainty is not whether MPAL exists, but how best to define and treat its biologically diverse forms. Diagnostic criteria have changed repeatedly, sample sizes are small, and adult and pediatric disease differ. The most defensible current interpretation is that MPAL comprises several genomic diseases converging on early-progenitor lineage plasticity, not one uniform cancer. This explains why immunophenotype alone is an imperfect treatment guide and why integrated flow cytometry, fusion testing, mutation profiling, epigenetic/transcriptomic characterization, and MRD are increasingly important. The 2024 single-cell data are promising for risk stratification, but MPAL95 and methylation-guided therapy require prospective validation before routine implementation. (sherban2025acuteleukemiaof pages 9-12, weinberg2024howtothink pages 5-6, peretz2024multiomicsinglecell pages 1-2)

Key source URLs and publication dates

• Weinberg, Hematology, December 2024: https://doi.org/10.1182/hematology.2024000554. (weinberg2024howtothink pages 5-6)
• Peretz et al., Nature Communications, September 2024: https://doi.org/10.1038/s41467-024-52317-2. (peretz2024multiomicsinglecell pages 1-2)
• Mumme et al., Genome Medicine, October 2023: https://doi.org/10.1186/s13073-023-01241-z. (mumme2023singlecellrnasequencing pages 1-2)
• Dickerson et al., Blood Cancer Discovery, March 2022: https://doi.org/10.1158/2643-3230.bcd-21-0163. (dickerson2022znf384fusiononcoproteins pages 15-15)
• Orgel et al., Cancer, 2020: https://doi.org/10.1002/cncr.32552. (orgel2020mixed‐phenotypeacuteleukemia pages 1-2)
• Oberley et al., Leukemia, February 2020: https://doi.org/10.1038/s41375-020-0741-0. (oberley2020significanceofminimal pages 1-2)
• Alexander et al., Nature, September 2018: https://doi.org/10.1038/s41586-018-0436-0. (sherban2025acuteleukemiaof pages 9-12)
• Takahashi et al., Nature Communications, July 2018: https://doi.org/10.1038/s41467-018-04924-z. (sherban2025acuteleukemiaof pages 9-12)

References

1. (sherban2025acuteleukemiaof pages 12-16): Adi Sherban and Ofir Wolach. Acute leukemia of ambiguous lineage: the known and the uncertain. Haematologica, 111:813-827, Oct 2025. URL: https://doi.org/10.3324/haematol.2025.287793, doi:10.3324/haematol.2025.287793. This article has 3 citations.

2. (sherban2025acuteleukemiaof pages 20-24): Adi Sherban and Ofir Wolach. Acute leukemia of ambiguous lineage: the known and the uncertain. Haematologica, 111:813-827, Oct 2025. URL: https://doi.org/10.3324/haematol.2025.287793, doi:10.3324/haematol.2025.287793. This article has 3 citations.

3. (sherban2025acuteleukemiaof pages 1-6): Adi Sherban and Ofir Wolach. Acute leukemia of ambiguous lineage: the known and the uncertain. Haematologica, 111:813-827, Oct 2025. URL: https://doi.org/10.3324/haematol.2025.287793, doi:10.3324/haematol.2025.287793. This article has 3 citations.

4. (mumme2023singlecellrnasequencing pages 1-2): Hope L. Mumme, Sunil S. Raikar, Swati S. Bhasin, Beena E. Thomas, Taylor Lawrence, Elizabeth P. Weinzierl, Yakun Pang, Deborah DeRyckere, Chuck Gawad, Daniel S. Wechsler, Christopher C. Porter, Sharon M. Castellino, Douglas K. Graham, and Manoj Bhasin. Single-cell rna sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia. Genome Medicine, Oct 2023. URL: https://doi.org/10.1186/s13073-023-01241-z, doi:10.1186/s13073-023-01241-z. This article has 20 citations and is from a highest quality peer-reviewed journal.

5. (peretz2024multiomicsinglecell pages 1-2): Cheryl A. C. Peretz, Vanessa E. Kennedy, Anushka Walia, Cyrille L. Delley, Andrew Koh, Elaine Tran, Iain C. Clark, Corey E. Hayford, Chris D’Amato, Yi Xue, Kristina M. Fontanez, Aaron A. May-Zhang, Trinity Smithers, Yigal Agam, Qian Wang, Hai-ping Dai, Ritu Roy, Aaron C. Logan, Alexander E. Perl, Adam Abate, Adam Olshen, and Catherine C. Smith. Multiomic single cell sequencing identifies stemlike nature of mixed phenotype acute leukemia. Nature Communications, Sep 2024. URL: https://doi.org/10.1038/s41467-024-52317-2, doi:10.1038/s41467-024-52317-2. This article has 24 citations and is from a highest quality peer-reviewed journal.

6. (weinberg2024howtothink pages 5-6): Olga K. Weinberg. How to think about acute leukemia of ambiguous lineage. Hematology, 2024:287-292, Dec 2024. URL: https://doi.org/10.1182/hematology.2024000554, doi:10.1182/hematology.2024000554. This article has 16 citations and is from a peer-reviewed journal.

7. (oberley2020significanceofminimal pages 2-3): Matthew J. Oberley, Sunil S. Raikar, Gerald B. Wertheim, Jemily Malvar, Richard Sposto, Karen R. Rabin, Jyotinder N. Punia, Alix E. Seif, Viviane C. Cahen, Reuven J. Schore, Dragos C. Luca, Terri Guinipero, William G. Woods, Maurice R. G. O’Gorman, and Etan Orgel. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multi-center cohort study. Leukemia, 34:1741-1750, Feb 2020. URL: https://doi.org/10.1038/s41375-020-0741-0, doi:10.1038/s41375-020-0741-0. This article has 28 citations and is from a highest quality peer-reviewed journal.

8. (sherban2025acuteleukemiaof pages 9-12): Adi Sherban and Ofir Wolach. Acute leukemia of ambiguous lineage: the known and the uncertain. Haematologica, 111:813-827, Oct 2025. URL: https://doi.org/10.3324/haematol.2025.287793, doi:10.3324/haematol.2025.287793. This article has 3 citations.

9. (sherban2025acuteleukemiaof pages 6-9): Adi Sherban and Ofir Wolach. Acute leukemia of ambiguous lineage: the known and the uncertain. Haematologica, 111:813-827, Oct 2025. URL: https://doi.org/10.3324/haematol.2025.287793, doi:10.3324/haematol.2025.287793. This article has 3 citations.

10. (orgel2020mixed‐phenotypeacuteleukemia pages 1-2): Etan Orgel, Thomas B. Alexander, Brent L. Wood, Samir B. Kahwash, Meenakshi Devidas, Yunfeng Dai, Todd A. Alonzo, Charles G. Mullighan, Hiroto Inaba, Stephen P. Hunger, Elizabeth A. Raetz, Alan S. Gamis, Karen R. Rabin, Andrew J. Carroll, Nyla A. Heerema, Jason N. Berman, William G. Woods, Mignon L. Loh, Patrick A. Zweidler‐McKay, and John T. Horan. Mixed‐phenotype acute leukemia: a cohort and consensus research strategy from the children’s oncology group acute leukemia of ambiguous lineage task force. Cancer, 126:593-601, Oct 2020. URL: https://doi.org/10.1002/cncr.32552, doi:10.1002/cncr.32552. This article has 79 citations and is from a domain leading peer-reviewed journal.

11. (oberley2020significanceofminimal pages 1-2): Matthew J. Oberley, Sunil S. Raikar, Gerald B. Wertheim, Jemily Malvar, Richard Sposto, Karen R. Rabin, Jyotinder N. Punia, Alix E. Seif, Viviane C. Cahen, Reuven J. Schore, Dragos C. Luca, Terri Guinipero, William G. Woods, Maurice R. G. O’Gorman, and Etan Orgel. Significance of minimal residual disease in pediatric mixed phenotype acute leukemia: a multi-center cohort study. Leukemia, 34:1741-1750, Feb 2020. URL: https://doi.org/10.1038/s41375-020-0741-0, doi:10.1038/s41375-020-0741-0. This article has 28 citations and is from a highest quality peer-reviewed journal.

12. (NCT07222579 chunk 3): Ashkan Emadi, MD PHD. Subcutaneous Blinatumomab for Treatment of Adult Patients With CD19-Positive Mixed Phenotype Acute Leukemia (MPAL). West Virginia University. 2026. ClinicalTrials.gov Identifier: NCT07222579

13. (NCT07517510 chunk 1): Qing Zhang. HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).. Guangdong Second Provincial General Hospital. 2026. ClinicalTrials.gov Identifier: NCT07517510

14. (NCT07573670 chunk 2): Chen Suning. A Phase 2 Study of Bcl-2 Inhibitor Combined With Azacitidine for Newly Diagnosed Mixed Phenotype Acute Leukemia. The First Affiliated Hospital of Soochow University. 2026. ClinicalTrials.gov Identifier: NCT07573670

15. (dickerson2022znf384fusiononcoproteins pages 15-15): Kirsten M. Dickerson, Chunxu Qu, Qingsong Gao, Ilaria Iacobucci, Zhaohui Gu, Hiroki Yoshihara, Emily A. Backhaus, Yunchao Chang, Laura J. Janke, Beisi Xu, Gang Wu, Evangelia K. Papachristou, Clive S. D'Santos, Kathryn G. Roberts, and Charles G. Mullighan. Znf384 fusion oncoproteins drive lineage aberrancy in acute leukemia. Blood cancer discovery, 3:240-263, Mar 2022. URL: https://doi.org/10.1158/2643-3230.bcd-21-0163, doi:10.1158/2643-3230.bcd-21-0163. This article has 46 citations and is from a peer-reviewed journal.

16. (OpenTargets Search: mixed phenotype acute leukemia): Open Targets Query (mixed phenotype acute leukemia, 10 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

17. (martin‐guerrero2019non‐leukemicpediatricmixed pages 1-4): Idoia Martin‐Guerrero, Itziar Salaverria, Birgit Burkhardt, Catherine Chassagne‐Clement, Monika Szczepanowski, Susanne Bens, Wolfram Klapper, Martin Zimmermann, Edita Kabickova, Yves Bertrand, Alfred Reiter, Reiner Siebert, and Ilske Oschlies. Non‐leukemic pediatric mixed phenotype acute leukemia/lymphoma: genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. Genes, Chromosomes and Cancer, 58(6):365-372, Jan 2019. URL: https://doi.org/10.1002/gcc.22726, doi:10.1002/gcc.22726. This article has 10 citations.

18. (martin‐guerrero2019non‐leukemicpediatricmixed pages 16-17): Idoia Martin‐Guerrero, Itziar Salaverria, Birgit Burkhardt, Catherine Chassagne‐Clement, Monika Szczepanowski, Susanne Bens, Wolfram Klapper, Martin Zimmermann, Edita Kabickova, Yves Bertrand, Alfred Reiter, Reiner Siebert, and Ilske Oschlies. Non‐leukemic pediatric mixed phenotype acute leukemia/lymphoma: genomic characterization and clinical outcome in a prospective trial for pediatric lymphoblastic lymphoma. Genes, Chromosomes and Cancer, 58(6):365-372, Jan 2019. URL: https://doi.org/10.1002/gcc.22726, doi:10.1002/gcc.22726. This article has 10 citations.

19. (mumme2023singlecellrnasequencing pages 4-5): Hope L. Mumme, Sunil S. Raikar, Swati S. Bhasin, Beena E. Thomas, Taylor Lawrence, Elizabeth P. Weinzierl, Yakun Pang, Deborah DeRyckere, Chuck Gawad, Daniel S. Wechsler, Christopher C. Porter, Sharon M. Castellino, Douglas K. Graham, and Manoj Bhasin. Single-cell rna sequencing distinctly characterizes the wide heterogeneity in pediatric mixed phenotype acute leukemia. Genome Medicine, Oct 2023. URL: https://doi.org/10.1186/s13073-023-01241-z, doi:10.1186/s13073-023-01241-z. This article has 20 citations and is from a highest quality peer-reviewed journal.

20. (NCT02135874 chunk 2): Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia. M.D. Anderson Cancer Center. 2014. ClinicalTrials.gov Identifier: NCT02135874

Artifacts

• Edison artifact artifact-00